Table 1.
Baseline characteristics of patients (All patients, n=56)
| Number of patients (%) | |
|---|---|
| Age, years | |
| Median (range) | 64 (29-82) |
| Sex | |
| Male | 38 (67.9%) |
| Female | 18 (32.1%) |
| ECOG performance status | |
| 0 | 32 (57.1%) |
| 1 | 20 (35.7%) |
| 2 | 4 (7.1%) |
| Disease status | |
| Initially metastatic | 39 (69.6%) |
| Recurrent | 17 (30.4%) |
| Site of primary tumor | |
| Ascending colon | 8 (14.3%) |
| Transverse colon | 7 (12.5%) |
| Descending colon | 5 (8.9%) |
| Recto-simoid colon | 32 (57.1%) |
| NA | 4 (7.1%) |
| Histological differentiation | |
| Well/moderate | 46 (82.1%) |
| Poor/undifferentiated | 8 (14.3%) |
| NA | 2 (3.6%) |
| Previous first-line treatment | |
| FOLFOX/FOLFIRI + cetuximab | 15 (26.8%) |
| FOLFOX/FOLFIRI + bevacizumab | 21 (37.5%) |
| FOLFOX/FOLFIRI | 20 (35.7%) |
| RAS mutation | |
| Wild type | 32 (57.1%) |
| Mutant | 14 (25.0%) |
| NA | 10 (17.9%) |
| Number of metastatic site | |
| 1-2 | 34 (60.7%) |
| ≥3 | 10 (17.9%) |
| NA | 12 (21.4%) |
ECOG: Eastern Cooperative Oncology Group; NA: not available; FOLFOX: 5-fluorouracil, leucovorin, and oxaliplatin; FOLFIRI: 5-fluorouracil, leucovorin, and irinotecan.